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The intestinal mucosa is unique in that it can be tolerant to the resident, symbiotic microbiota but remaining, at the same time,
responsive to and able to ﬁght pathogens. The close interaction between host-symbiotic microbiota at the mucosal level poses
important challenges since microbial breaches through the gut barrier can result in the breakdown of gut homeostasis. In this
paper, hosts-integrated components that help to preserve intestinal homeostasis including barrier and immune function are
discussed. In addition global alterations of the microbiota that can play a role in the initiation of an exaggerated inﬂammatory
response through an abnormal signaling of the innate and adaptive immune response are brieﬂy described.
1.Introduction
The close association of dense bacterial communities of
the gut with the mucosa at diﬀerent habitats of the distal
intestine are the basis of symbiotic interactions between
the host and its microbiota. Host factors encourage the
establishment of the microbiota preserving at the same
time tissular homeostasis. The magnitude and the diversity
of intestinal microﬂora represent yet a threat of microbial
break through the single-cell epithelial layer that covers the
intestinal surface [1]. The invasion of host tissue by resident
bacteria would certainly result in the breakdown of the
symbiotic host-microbiota interactions.
Commensal invasion of the intestinal tissues is a rare
event during the homeostatic situation or occurs in a
very limited and controlled manner [2–4]. In some major
disturbances of gut balance and integrity it results in
severe clinical conditions such as bacteraemia, necrotising
enterocolitis in the newborn period, or chronic local or
systemic inﬂammatory conditions.
A diversity of components contributes to the preser-
vation of the barrier integrity. Cellular and extracellular
host components at the intestinal mucosa participate in the
prevention of bacterial leakage from the lumen. Working
in concert with the barrier function, the immunological
tolerance to commensals sustains the symbiotic microbiota-
host interactions.
The intestinal immune system is tolerant to the compo-
nentsofthecommensalmicrobiota,howeverimmunological
tolerance is not the result of immunological ignorance.
In fact commensals stimulate host reactions that do not
p r o m o t eh o s tt i s s u ed a m a g eb u tr a t h e rc y t o p r o t e c t i v em e c h -
anisms at the mucosal environment [5, 6]. Thus, systemic
immune tolerance concurs with local host responses to com-
mensal bacteria that strengthen the barrier function main-
taining the microbiota within the intestinal environment
through mechanisms that do not stimulate inﬂammation.
This is the result of permanent interactions between the host
and its commensal microbiota [7].
Abasicfunctionalfeatureoftheintestineimmunesystem
is to avoid tissue-damaging overreactions to commensals
that would unnecessarily damage intestinal tissues by way
of inﬂammatory processes, at the same time the intestinal
barrier and the innate immune defense needs to be eﬀective
regarding the distinct recognition of commensals from
pathogens.2 International Journal of Inﬂammation
Microbial-associated molecular patterns (MAMPs) or
“infectious nonself” [8–11] are broadly shared molecular
motifs expressed on most bacteria either commensal or
pathogens. They interact with pattern recognition receptors
(PRRs), expressed on epithelial cells or innate mucosal
immune cells such as macrophages and dendritic cells [12].
PRRs are germ-line encoded molecules that are expressed
on the plasma membrane or in intracellular endosomal
compartments, that is, Toll-like receptors (TLRs) [11], or
cytosolic molecules such as nucleotide-binding oligomeriza-
tion domain (NOD) [13].
The best characterized PRRs are the family of TLRs
but, as mentioned above, other families of PRRs have
been described. Together they can sense the presence of
bacteria in the extracellular and intracellular compartments
[11, 13, 14].
Several MAMPs that are ligands for PRRs are common
to pathogens and commensal microorganisms and yet, the
intestine initiates a protective response to the former while
allowing an important and complex microbiota to establish
itself at the intestinal surface without any detrimental
eﬀect on homeostasis. Discrimination between pathogens
and commensals clearly involves other mechanisms. The
expression and engagement of PRRs in diﬀerent cellular or
diﬀerent plasma membrane compartments [15], as well as
the presence of additional “danger signals” from stressed or
damagedtissues,maybeimportantdeterminingfactors[16].
Certainly, most pathogens express a number of virulence
determinants such as adherence to and invasion of host cells,
and the production of toxins. An important virulence trait
of pathogens like Salmonella and Shigella is their capacity to
access the intracellular environment where they interact with
cytosolic PRRs that are part of the inﬂammasome molecular
complex [14, 16].
Inthispaperwewilldiscussthemechanismsthatprevent
immune/inﬂammatory reactions against commensals as well
as evidences of deviations to this that contribute to IBD.
We will focus on (1) mechanisms that limit direct bacterial
contactwithepithelialcellsurfaceseitherbyasecretedmucus
layer or the fast clearance of bacterial cells, (2) bacterial
dysbiosis commonly associated to pathological conditions,
and (3) the modulation of the innate/inﬂammatory reaction
to commensals.
2.IntestinalMucosalFactorsInvolvedin
Host-MicrobiotaHomeostasis
Large quantities of bacteria reside in the gut lumen with-
out initiating any detrimental inﬂammatory response [17]
whereas low numbers of bacteria in blood or tissues trigger
an energetic inﬂammatory response.
The intestinal homeostasis is achieved through robust
cellular and molecular mechanisms that contribute to
reinforce the intestinal barrier function through secreted
products, promote cytoprotective epithelial responses, and
innate immune reactions to commensals for clearance of
physiological passage of bacteria and modulation of detri-
mental inﬂammatory response (Figure 1).
2.1. Mucosal Secreted Barrier. On the luminal side of the
epithelial cells, a series of interacting factors work together
for the prevention of mucosal bacteria close juxtaposition to
host tissues.
One of the ﬁrst physical contacts between the host and
the luminal bacteria is the intestinal mucus layer, which
covers the mucosal surface. This mucus is a product of
goblet cells that actively secrete the mucin glycoproteins. The
secretedbarrieriscomposedprimarilybyhighlyglycosylated
multimeric glycoproteins produced by goblet cells which are
responsible for the viscosity of the mucus [18], but also
by other secreted compounds like phospholipids, lectins,
immunoglobulins, and antimicrobial peptides (defensins,
lysozyme, and cathelicidins).
2.1.1. Mucins. Increasing evidences from animal models
show that intestinal inﬂammation could result from defects
in this physical interface (both the secreted and the cellular
barriers), even in the presence of normal microbiota and
normal innate and adaptive immunity [19–21]. Therefore,
it is not surprising that an important area of research on
inﬂammatory bowel diseases has focused on failures in the
intestinalbarrierfunctioninordertoelucidatewhetherthese
dysfunctions are primary contributors to the inﬂammation
or a consequence of the inﬂammatory reaction [22]. This,
however, has not been an easy task. The investigation of
the secreted barrier is troubled with technical sampling
problems; most studies fail to preserve the architecture of
the mucus layer [23]. Similarly, the deﬁnition of the mucosa-
associated bacteria and the location of the microbes in the
mucus layer remain controversial because the procedure
to collect the biopsies lacks consistency from one study
to another, as it has been previously indicated [24]. For
instance, the preparation of the subject for the colonoscopy
can impact the composition of the bowel community [25],
the preparative ﬂuid may still be present in the bowel making
diﬃcult to distinguish what is actually being collected [26],
bacteria from the outer mucus layer can be easily dislodged
and lost during the preparation of the sample [25], and so
forth. It seems that at least the inner mucus layer remains
quasisterile [27, 28] with most of the microbes residing at
least 800μm from the surface of the mucosal epithelial cells
[29].
It has been suggested that the contribution of the
intestinal bacteria to the pathogenesis of inﬂammatory
bowel disease could be by increased penetration in the
mucus, increased adherence to epithelial cells, or invasion
of the epithelium. Schultsz et al. [30] studied the spatial
distribution of bacteria in the mucosa of rectal specimens
from IBD patients and controls. They observed that bacteria
were localised within the mucus layer but did not adhere to
epithelial cells and were not present in the lamina propria.
They conclude that the intestinal mucus in IBD patients is
less protective against endogenous bacteria than in healthy
individuals, which could explain the increased association
of luminal bacteria with the mucus layer [31]. The reduced
protection of the mucus could be a result of a genetically
determined alteration, for example, in the glycosylation of
glycoproteins that renders the mucus prone to degradation,International Journal of Inﬂammation 3
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Figure 1: Components of the gut barrier.
or a depletion of speciﬁc mucin subspecies [32, 33]. Various
changes of the mucus properties have been documented
since mid 80s [28, 34–37]. Jacobs and Huber observed that
ulcerative colitis patients had an altered glycosylated mucin
[38]. Fyderek and colleagues showed that the thickness of
the mucus layer of adolescents with IBD was three times
thinner in both CD and UC patients compared to controls
[39].Inulcerativecolitis,thereisadecreasedmucinsulfation
[34].
2.1.2. Antimicrobial Peptides. The antimicrobial peptides
provide protection from intestinal infections and contribute
to the maintenance of enteric homeostasis; the concentra-
tions of the diﬀerent products show a decreasing gradient
within the mucin gel from the epithelial side to the luminal
side [22].
Paneth cells and other mucosal cell types such as
enterocytes, colonocytes, and goblet cells are the source
of antimicrobial peptides [40]. The importance of these
compounds in the susceptibility to mucosal infections has
been demonstrated using experimental models [41]. There
are two major groups of antimicrobial peptides in humans
and other mammals: defensins and cathelicidins [42]w h i c h
are also active in cell signaling.
The α-, β-, and θ-defensins kill bacteria by membrane
disruption [42]. The cysteine-rich α-defensins also known
as cryptdins [43] are produced as an inactive precursor
that requires activation by matrilysin in the small intestine
[44]. Experimental models show that α-defensins con-
tribute to host defence by inﬂuencing the composition
and limiting the numbers of resident microbes [45]a n d
in rodents have microbicidal activity against Escherichia
coli, Staphylococcus aureus, and Salmonella typhimurium.
The nucleotide-binding oligomerization domain-containing
protein 2 (NOD2) controls the expression of a distinct
subsets of α-defensins and defensin-related cryptdins by
Paneth cells [46] upon bacterial ligand recognition. It has
been shown that some patients with IBD suﬀer from an
impairedsynthesisofα-defensins[47]associatedwithNOD2
variants [13].
Expression of β-defensins HBD 2 and 3 is induced in
the case of inﬂammation or infection [48]. The induction
is mediated by proinﬂammatory cytokines like IL-1β and
bacterial signaling through the activation of TLRs. Thus,
extracellularand intracellular cellsignaling are both involved
inthestimulationofbactericidalproductsecretionbyPaneth
and superﬁcial epithelial cells.
Cathelicidins, the other main family of antimicrobial
peptides, are characterized by an N-terminal signal peptide
(cathelin prosequence) and a structurally variable cationic
peptide at the C-terminus [41, 42, 49]. The human mature
cathelicidin is called LL-37, and it is originated from a
precursor molecule that requires proteolytic activation. The
processed peptide has antimicrobial activity against Gram-
negative and Gram-positive bacteria [50]. It is expressed by4 International Journal of Inﬂammation
gastric epithelial cells, distal small bowel enterocytes, and
throughout the colon.
Another homeostatic product that controls microbiota
overall size and composition is the production of regenerat-
ingislet3gamma(RegIIIγ),aC-typelectinwithbactericidal
properties [51]. In fact, Reg III γ and the human homolog
HIP/PAP bind to peptidoglycan component of bacteria
particularly of Gram-positive bacteria resulting in bacterial
killing.RegIIIγ expressiondependsonepithelialstimulation
through TLRs ligands to epithelial [5]. It is possible that Reg
III γ ﬁlls a particular antibacterial niche because it targets
Gram-positive bacteria such as Enterococcus fecalis [51].
The maintenance of intestinal homeostasis depends
also on host-microbial interactions that involve protein-
carbohydrate recognition [52]. Some animal lectins function
as PRR, in the same way that TLRs and NODs do. They
cover a wide range of host-microbial interactions. Soluble-
and membrane-associated lectins mediate interactions with
microorganisms that may lead to mutualistic interactions
(commensalism or symbiosis), host colonization, immune
recognition by the host, or “subversion” of the nonself
recognition functions [52].
Galectins, a subtype of lectins, appear to play important
functions in the innate and adaptive immune response at
the intestinal mucosa. They are expressed by dendritic cells,
macrophages, mast cells, natural killer cells, gamma/delta T
cells, and B1 cells, as well as cells from the adaptive immune
system (activated B and T cells) [53]. Although galectins lack
a typical secretion signal peptide, they are present not only
in the cytosol and the nucleus, but also in the extracellular
space. Galectin 1 displays anti-inﬂammatory activities by
blocking or attenuating signalling events that lead to leuko-
cyterecruitment,migration,andinﬁltration[53].Ithasbeen
shown that galectin-1 can drive the diﬀerentiation of DCs
with a regulatory phenotype and function; in fact they can
induce T cell tolerance, blunt TH-17 and TH1 responses and
suppress autoimmune inﬂammation through mechanisms
involving IL-27 and IL-10 [54].
Galectins can interact directly with bacterial surface
glycans in the lumen of the gut or more speciﬁcally in the
mucus environment. A recent observation has underlined
the capacity of galectins to kill bacteria in the lumen of the
gut [55]. Both Gram-positive bacteria, such as Streptococcus
pneumoniae, and Gram-negative bacteria, such as Klebsiella
pneumoniae, Neisseria meningitidis, Neisseria gonorrhoeae,
Haemophilus inﬂuenzae,a n dPseudomonas aeruginosa, dis-
play surface carbohydrate galectin ligands [52].
Many human pathogens express on their surfaces diverse
carbohydrate structures, and many of these structures
have similarities to human antigens, a mechanism utilized
by both commensal and pathogens to render themselves
immunologically inert. However galectins give the host the
opportunity to overcome the pathogenic strategy. In vitro
and in vivo results demonstrate that Gal-4 and Gal-8 possess
the ability to speciﬁcally kill bacteria expressing blood group
antigens.Forexample,theyrecognizeandkillEscherichiacoli
expressing human blood group antigens while failing to alter
the viability of otherE.coli strains or other Gram-negative or
Gram-positive organisms [56]. The ability of Gal-4 and Gal-
8 to also kill α-Gal-expressing bacteria shows that galectin-
mediated killing is not limited to human blood group
antigen-expressing bacteria and suggests that galectins may
aﬀect the composition of multiple populations of intestinal
bacteria, thereby modulating the intestinal microbiota.
2.1.3. Secretory Antibodies. The third mechanism for the
luminal sequestering of symbiotic bacteria involves secretory
antibodies in particular secretory immunoglobulin A (sIgA).
sIgA-coated bacteria have lower chances to become associ-
ated with the intestinal epithelial surface. Suzuki et al. have
shown that secretions of IgA are as or more important than
innateantimicrobialpeptidesintheregulationofcommensal
bacterial ﬂora. In fact in induced cytidine deaminase (AID)
deﬁciency in mice, the absence of hypermutated IgA results
in two diﬀerent consequences: (a) a production of large
amounts of unmutated IgM and (b) higher colonization
of segmented ﬁlamentous bacteria of the intestine. In turn
this abnormal level of colonization results in a strong and
abnormal stimulation of the mucosal immune system [57].
HypermutatedIgAspeciﬁcforcomponentsofthemicro-
biota involves bacterial sampling by DC and a limited
m i g r a t i o no fD Cu pt ot h em e s e n t e r i cl y m p hn o d e sw h e r e
B cells are induced to diﬀerentiate into plasma cells [7, 58].
Lamina propria plasma cells produced dimeric IgA that is
shuttled to the apical side of the enterocytes by the polymeric
immunoglobulin receptor or secretory component.
2.2. The Cellular Barrier. Despite the multiple components
of the secreted barrier to prevent bacterial contact with
the epithelial layer occasional breaches are inevitable. Thus
a second layer of the intestinal immune protection is the
rapid detection and clearance of bacteria that penetrate the
epithelial layer or go beyond it and into the lamina propria.
Bacterial invasion of epithelial cells or breach of the
epithelialbarrierprovidesasignaltoepithelialcellstoinitiate
responses that are of inﬂammatory nature in the majority of
the cases and whose ﬁnal goal is the clearance of invading
microorganisms. The epithelial layer seems to play a critical
role in the recognition between commensals and pathogens.
It is essential that the immune system recognizes and reacts
to bacterial associated “danger signals” but remains tolerant
to nonthreatening microbes and host cells [12], and the
epithelial layer plays an important role.
Nonpathogenic bacteria induce a limited immune reac-
tion on enterocytes, with only a transient innate component
[15] that may contribute to the physiological, low-level
inﬂammation in the intestine. In addition they induce
the secretion of homeostatic cytokines in the mucosal
microenvironment[59].Incontrast,truepathogensinducea
rapidandmoreaggressiveresponsethatinvolvesintracellular
signaling pathways that detect cellular injury, also called
“danger signals” [12]. Taken together, the host response at
the epithelial layer can thus be considered as a two-tiered
process which in a ﬁrst instance, involves proinﬂammatory
genes that are triggered by most bacteria, pathogenic or
not. Subsequent activation of a second cluster of genes is
deﬁned by speciﬁc virulence traits of the microorganismInternational Journal of Inﬂammation 5
[10]. In fact the epithelium has a central role in the initiation
of the inﬂammation in response to bacterial pathogens.
For example IL-8 derived from epithelial cells initiates the
inﬂammatory response and tissue damage. However this is
necessary for the clearance of invading microorganisms [60]
by neutrophils.
A limited number of commensals can physiologically
breach the epithelial barrier. When this happens they are
taken up and killed by lamina propria macrophages. LP
macrophages can clear bacteria without triggering a strong
inﬂammatory reaction [61]. In addition upon bacterial
breaching of the epithelial barrier, LP macrophages migrate
andproducegrowthfactorsfortheepithelialrestitution[62].
The lamina propria macrophages that express low CD14 are
a major cellular component of the mucosal homeostasis.
Another cell type that interacts with commensal bacteria
are the dendritic cells [63]. A population of DC—CX3CR1+
DCs—are closely associated with the epithelial lining. In
fact CX3CR1+ DCs extend transepithelial dendrites into the
gut lumen to sample and process luminal Ags including
components of the microbiota [3, 4]. In addition CX3CR1+
DCs initiate the host defence to intestinal pathogens, such
as Salmonella, as shown by the enhanced susceptibility of
CX3CR1-deﬁcient animals to Salmonella infection [64].
The interactions of DCs with T cells mediate the
initiation of the adaptive immune response. In addition
to lamina propria DC, a rare population of white blood
cells have a crucial role in determining the nature of
immune reactions and in ﬁne-tuning the balance between
immunologic tolerance or induction of inﬂammation upon
recognition of commensals or pathogens, respectively. This
functional dualism is crucial at the intestinal level where
the immune system does not react against commensals but
should be still reactive to clear pathogens upon challenge.
A long-standing question has been how dendritic cells drive
these distinct immune outcomes required for the clearance
of pathogens. Recently, CD103+ (the α E chain of the
αEb7 integrin) small intestine lamina propria (siLP) DCs
are potent inducers of homing receptors (CCR9 and the
α4b7 integrin) on (CD4 and CD8) T and IgA+ B cells.
These subsets have the enhanced capacity to induce the
diﬀerentiation of Foxp3-expressing regulatory T (Treg) cells.
In part, this process is driven by vitamin A metabolite
retinoic acid [63], and it is crucial in the immunological
tolerance to preserve tissue homeostasis.
CD4+ regulatory T cells are essential components of
the host-microbiota symbiosis. The two main subtypes of T
Reg cells are CD4+FoXP3+ T Reg cells that are found in the
colon and small intestinal lamina propria and CD4+FoXP3–
Il-10+ T Reg cells that are found in the small intestinal
intraepithelial and lamina propria compartments [65].
Colonic FoXP3+ T Reg cells express Il-10, which reciprocally
inhibits TH17 and TH1 cells.
2.3. Dysbiosis. The essential role of bacteria in the patho-
genesis of colitis has achieved a general consensus. Although
animalmodelsofcolitisdonotmimicexactlyCrohn’sdisease
or ulcerative colitis, they provide one of the best evidences
of the direct or indirect etiological role of bacteria in
IBD. Human studies, however, have not been so conclusive.
Even if these studies have failed to reveal categorically a
speciﬁc altered composition on the microbial makeup of
IBD patients versus control subjects, either in the stools
or associated to biopsies, they support the hypothesis that
a general “dysbiosis” underlies IBD. This term has been
largely used since the late 50s and 60s to deﬁne deviations
of the “normal” bacterial ﬂora under antibiotic treatment
in infants, adults, and patients in intensive care [66, 67].
In a healthy individual, the fecal bacterial community has a
remarkable stability. This has been largely reported during
the last years [68–71]. In contrast, a relatively unstable
microbiota has been shown in Crohn’s disease patients [72–
74]. The presence of “unusual” bacteria was associated to the
disease, for instance, low proportions of Firmicutes particu-
larly C. leptum, high proportions of Gram-negative bacteria
[75], conﬂicting information about B. vulgatus [74, 76],
reduced concentration of F. prausnitzii [77], and increased
numbers of Enterobacteria [72, 78]. Little information is
available with regards to ulcerative colitis, but it seems
to follow the same trend in that UC patients have a less
diverse bacterial community [75, 79]. Pyrosequencing data
of healthy and IBD patients show that the distribution of
bacterial species diﬀered only slightly between disease states
(i.e., Crohn’s disease versus ulcerative colitis) with regards to
anatomic sites. The IBD group had marked decreases in the
main representatives of the gut community: Bacteroidetes
and Firmicutes [80].
Similarly, a dysbiosis was described on mucosal biopsies
fromIBDpatients.Bacteriafromthesesiteshavebeenshown
to diﬀer from the luminal bacteria [81, 82].
The group of Schreiber [83]r e p o r t e dar e d u c t i o ni n
the microbial diversity in mucosal specimens from Crohn’s
disease patients reﬂected in a reduction in the number of
DGGE bands and in the diversity indices. Notwithstanding
somecontradictoryresultsreportedbydiﬀerentlaboratories,
a common ﬁnding seems to be an increased concentration of
total bacteria both in CD and UC [30, 84–87].
Some reports argue against a localized dysbiosis to
explain the patchy distribution of mucosal lesions [26, 88]
or crypt abscesses [89]. One report suggests the contrary, but
in this case biopsy samples from inﬂamed and noninﬂamed
sites were pooled before the analysis [90].
In conclusion, despite the exponential evolution of
technological approaches, the complex gut ecosystem still
remains enigmatic. Eﬀorts in deciphering its impact on IBD
suggest that restoring shifts from the “normal” commensal
microbiota rather than focusing on one particular member
may improve these conditions.
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